Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

The TEMPO-MIBC trial is a phase III, single-center, two-arm, randomized, controlled trial. Its primary objective is to evaluate the efficacy of a simplified diagnostic and treatment pathway for muscle-invasive bladder cancer (MIBC). This study investigates the role of multiparametric bladder MRI (mpMRI) in patients with biopsy proven cancer of the bladder with clinical features of detrusor muscle invasion. In the experimental arm, enrolled patients will receive a bladder mpMRI, if this exam will confirm the high suspicion of muscle invasion a conventional endoscopic transurethral resection of

Trial Details

NCT ID
NCT07067749
Phase
PHASE3
Sponsor
University of Rome Tor Vergata
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • multiparametric magnetic resonance imaging (mpMRI) of the bladder
  • Transurethral resection of bladder tumour (TURBt)
  • Circulating tumour DNA levels assessment
Locations (sample)
  • Rome, RM, Italy|41.89193,12.51133

Key Eligibility Criteria

  • Clinical suspicion of muscle invasive bladder cancer at cystoscopy and pre-cystoscopy imaging

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →